Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
Rutgers, The State University of New Jersey Clinical Research Center, New Brunswick, New Jersey